Novel Preclinical Research Tools Provide Humanized Immune Response to Advance Immunotherapeutic Development, Live Webinar Hosted by Crown Bioscience
SANTA CLARA, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces a live webinar to be presented by Dr. Michelle Mack, Director of Global Scientific Engagement, entitled "Beyond Syngeneics - Novel Tools for Addressing Human Specificity in Immuno-Oncology."
Checkpoint inhibitors like anti-PD-1, anti-PD-L1, and anti-CTLA-4 have revolutionized cancer treatment and have recently gained approval in several cancer types. Despite their potential, immunotherapies face significant development challenges due to the specificity and complexity of the human immune system upon which they act. Crown Bioscience has generated innovative research models to address these obstacles early during preclinical drug development.
This webinar will introduce novel tools for investigating human immune response in immunocompetent systems. This platform includes models that express humanized immune checkpoint inhibitors and ligands created via CRISPR/Cas9 gene editing. The validation of the platform will be detailed to demonstrate its reliability and utility to inform immuno-oncology efficacy studies.
"Crown Biosciences recognizes the importance of providing innovative tools for the evaluation of new therapies, especially in complex applications like immuno-oncology," said Laurie Heilmann, Chief Business Officer at Crown Bioscience. "By attending this webinar, researchers will learn how to use our unique platform to transform their preclinical immunotherapeutic programs."
Join Dr. Mack on Tuesday, October 31 at 10:00 am EDT for an informative session. For details or to register for this complimentary event, visit: Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
About Dr. Michelle Mack
Michelle Mack, Director of Scientific Engagement at Crown Bioscience brings 15 years of previous Oncology R & D experience from Pfizer Inc., where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included: small-molecule inhibitors, antibody drug conjugates and nanoparticle based therapeutics. Michelle's scientific expertise spans the preclinical and translational space for multiple solid and hematological tumor indications. Throughout her professional career, Michelle has worked in Oncology, Immunology and Immuno-Oncology therapeutic areas. She has several high-impact peer-reviewed publications and has led discussions at multiple scientific conferences.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Prosafe SE: Operational Update - March 202419.3.2024 13:27:59 CET | Press release
Fleet utilization for February 2024 was 55.9 percent. Safe Notos, Safe Zephyrus and Safe Concordia had utilization of 100 percent in February. Safe Eurus had utilization of 91.3 percent in February due to a repair that was completed during the month. Safe Caledonia is laid up at Scapa Flow in the UK pending future work. Safe Boreas and Safe Scandinavia are laid up in Norway pending future work Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com Stavanger, 19 March 2024 Prosafe SE For further information, please contact: Terje Askvig, CEO Phone: +47 952 03 886 Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Inside Information: Manu Skyttä, new President and CEO of Aspocomp Group Plc, will assume his duties on May 20, 202419.3.2024 13:25:00 CET | Press release
Aspocomp Group Plc, Inside Information, March 19, 2024 at 2:25 p.m. “We are pleased that Manu Skyttä will take up his position as President and CEO of Aspocomp in May. With his character, competence and energy, Mr. Skyttä strengthens Aspocomp’s strategy as a trusted supplier of demanding circuit board technology to all Aspocomp customers. At this point, I would like to thank Mikko Montonen on behalf of the entire Board for his long-term commitment to Aspocomp,” says Päivi Marttila, Chair of Aspocomp’s Board. Manu Skyttä succeeds Mikko Montonen, who, as previously announced, has agreed with the Board of Directors to step down from the role of President and CEO of the company. Mr. Montonen has committed to staying on as the company's President and CEO until May 20, 2024. For further information, please contact Päivi Marttila, the Chair of the Board of Directors, tel. +358 40 028 5358. ASPOCOMP GROUP PLC Board of Directors Aspocomp – heart of your technology A printed circuit board (PCB)
Investeringsforvaltningsaftale med BI Management A/S er godkendt af Finanstilsynet19.3.2024 13:15:48 CET | pressemeddelelse
PFA Asset Management A/S offentliggjorde i selskabsmeddelelse af 22. januar 2024, at Investeringsforeningen PFA Invests (”Foreningen”) bestyrelse havde besluttet at udpege BI Management A/S som investeringsforvaltningsselskab for Foreningen. Finanstilsynet har godkendt valget af BI Management A/S som nyt investeringsforvaltningsselskab for Foreningen. BI Management A/S vil overtage rollen som investeringsforvaltningsselskab seneste ved udgangen af andet kvartal 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Rasmus Bessing. Med venlig hilsen PFA Asset Management A/S Rasmus Bessing Direktør
Offentliggørelse af bestyrelsens redegørelse19.3.2024 13:05:00 CET | pressemeddelelse
Selskabsmeddelelse nr. 8-2023/24 19. marts 2024 MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER UDLEVERES DIREKTE ELLER INDIREKTE I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF GÆLDENDE LOVGIVNING ELLER REGLER I DEN PÅGÆLDENDE JURISDIKTION, HERUNDER I USA Offentliggørelse af bestyrelsens redegørelse Med henvisning til InterMail A/S' ("InterMail") meddelelse af 5. marts 2024 (nr. 7-2023/24) om offentliggørelse af tilbudsdokumentet vedrørende det frivillige offentlige overtagelsestilbud på InterMail fremsat af CapHold 4 inv ApS ("Tilbuddet"), offentliggør InterMail i dag bestyrelsens redegørelse om Tilbuddet ("Redegørelsen") i henhold til § 22 i bekendtgørelse nr. 636/2020 om overtagelsestilbud. Redegørelsen indeholder bestyrelsens holdning til tilbuddet og begrundelsen herfor, herunder bestyrelsens holdning til konsekvenserne for alle selskabets interessenter og til tilbudsgivers strategiske planer for målselskabet samt disses sandsynlige konsekvenser for beskæftige
Zoom Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 202419.3.2024 13:04:05 CET | Press release
SAN JOSE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. These organizations are setting new standards and achieving remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions. “At Zoom, we continue to innovate rapidly and are doubling down on our commitment to offering an AI-powered collaboration platform that delivers limitless human connection, reimagines teamwork, and strengthens customer connections,” said Smita Hashim, chief product officer at Zoom. “Fast Company’s recognition further validates our mission and dedication to providing our customers with choice and a high-quality, open collaboration platform power